Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tango Therapeutics (TNGX) Share-based Compensation (2020 - 2025)

Tango Therapeutics has reported Share-based Compensation over the past 6 years, most recently at $6.0 million for Q4 2025.

  • Quarterly results put Share-based Compensation at $6.0 million for Q4 2025, down 19.86% from a year ago — trailing twelve months through Dec 2025 was $26.4 million (down 8.54% YoY), and the annual figure for FY2025 was $26.4 million, down 8.54%.
  • Share-based Compensation for Q4 2025 was $6.0 million at Tango Therapeutics, down from $6.6 million in the prior quarter.
  • Over the last five years, Share-based Compensation for TNGX hit a ceiling of $7.5 million in Q2 2024 and a floor of $950000.0 in Q1 2021.
  • Median Share-based Compensation over the past 5 years was $4.9 million (2023), compared with a mean of $4.8 million.
  • Biggest five-year swings in Share-based Compensation: surged 720.57% in 2021 and later decreased 19.86% in 2025.
  • Tango Therapeutics' Share-based Compensation stood at $2.3 million in 2021, then soared by 67.7% to $3.8 million in 2022, then rose by 28.9% to $4.9 million in 2023, then surged by 52.94% to $7.5 million in 2024, then decreased by 19.86% to $6.0 million in 2025.
  • The last three reported values for Share-based Compensation were $6.0 million (Q4 2025), $6.6 million (Q3 2025), and $6.6 million (Q2 2025) per Business Quant data.